贝派地酸用于他汀不耐受患者心血管事件的一级预防
这项掩蔽随机临床试验纳入13970例他汀不耐受患者,其中4206例为一级预防患者,随机接受贝派地酸180 mg每日一次或安慰剂。中位随访39.9个月,贝派地酸组主要终点事件111例(5.3%) vs 安慰剂组161例(7.6%),校正HR 0.70(95%CI 0.55-0.89),P=0.002;不良事件包括痛风、胆石症及血清肌酐、尿酸和肝酶升高。
要点
- 贝派地酸使一级预防患者主要心血管复合终点风险降低,校正HR 0.70(95%CI 0.55-0.89)。
- 心血管死亡、心梗或卒中复合终点HR 0.64(95%CI 0.48-0.84),P<0.001。
- 贝派地酸组痛风(2.6% vs 2.0%)、胆石症(2.5% vs 1.1%)发生率高于安慰剂组。
核心结论
- 在高风险一级预防患者亚组中,贝派地酸治疗与主要心血管事件减少相关。
研究设计与样本
- 掩蔽随机临床试验,纳入13970例他汀不耐受患者,其中4206例为一级预防患者,随机接受口服贝派地酸180 mg每日一次(n=2100)或匹配安慰剂(n=2106)。
- 研究于2016年12月至2019年8月在32个国家1250个中心入组,中位随访39.9个月。
主要发现
- 主要终点(心血管死亡、非致死性心肌梗死、非致死性卒中或冠状动脉血运重建复合终点)事件:贝派地酸组111例(5.3%) vs 安慰剂组161例(7.6%),校正HR 0.70(95%CI 0.55-0.89),P=0.002。
- 心血管死亡、心肌梗死或卒中复合终点:贝派地酸组83例(4.0%) vs 安慰剂组134例(6.4%),HR 0.64(95%CI 0.48-0.84),P<0.001。
- 心肌梗死:贝派地酸组29例(1.4%) vs 安慰剂组47例(2.2%),HR 0.61(95%CI 0.39-0.98)。
- 心血管死亡:贝派地酸组37例(1.8%) vs 安慰剂组65例(3.1%),HR 0.61(95%CI 0.41-0.92);全因死亡:贝派地酸组75例(3.6%) vs 安慰剂组109例(5.2%),HR 0.73(95%CI 0.54-0.98)。
- 卒中或冠状动脉血运重建无显著影响;贝派地酸组痛风(2.6% vs 2.0%)、胆石症(2.5% vs 1.1%)发生率更高,血清肌酐、尿酸和肝酶水平升高。
关键数值与推荐
- 主要终点校正HR 0.70(95%CI 0.55-0.89),P=0.002;心血管死亡、心肌梗死或卒中复合终点HR 0.64(95%CI 0.48-0.84),P<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients without a prior cardiovascular event (primary prevention) have not been fully described. OBJECTIVE: To determine the effects of bempedoic acid on cardiovascular outcomes in primary prevention patients. DESIGN, SETTING, AND PARTICIPANTS: This masked, randomized clinical trial enrolled 13 970 statin-intolerant patients (enrollment December 2016 to August 2019 at 1250 centers in 32 countries), including 4206 primary prevention patients. INTERVENTIONS: Participants were randomized to oral bempedoic acid, 180 mg daily (n = 2100), or matching placebo (n = 2106). MAIN OUTCOME MEASURES: The primary efficacy measure was the time from randomization to the first occurrence of any component of a composite of cardiovascular death, nonfatal myocardial infarction (MI), nonfatal stroke, or coronary revascularization. RESULTS: Mean participant age was 68 years, 59% were female, and 66% had diabetes. From a mean baseline of 142.2 mg/dL, compared with placebo, bempedoic acid reduced low-density lipoprotein cholesterol levels by 30.2 mg/dL (21.3%) and high-sensitivity C-reactive protein levels by 0.56 mg/L (21.5%), from a median baseline of 2.4 mg/L. Follow-up for a median of 39.9 months was associated with a significant risk reduction for the primary end point (111 events [5.3%] vs 161 events [7.6%]; adjusted hazard ratio [HR], 0.70 [95% CI, 0.55-0.89]; P = .002) and key secondary end points, including the composite of cardiovascular death, MI, or stroke (83 events [4.0%] vs 134 events [6.4%]; HR, 0.64 [95% CI, 0.48-0.84]; P < .001); MI (29 events [1.4%] vs 47 events [2.2%]; HR, 0.61 [95% CI, 0.39-0.98]); cardiovascular death (37 events [1.8%] vs 65 events [3.1%]; HR, 0.61 [95% CI, 0.41-0.92]); and all-cause mortality (75 events [3.6%] vs 109 events [5.2%]; HR, 0.73 [95% CI, 0.54-0.98]). There was no significant effect on stroke or coronary revascularization. Adverse effects with bempedoic acid included a higher incidence of gout (2.6% vs 2.0%), cholelithiasis (2.5% vs 1.1%), and increases in serum creatinine, uric acid, and hepatic enzyme levels. CONCLUSIONS: In a subgroup of high-risk primary prevention patients, bempedoic acid treatment was associated with reduced major cardiovascular events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02993406.
引用
- Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA. 2023. PMID: 37354546. doi:10.1001/jama.2023.9696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。